Evidence map›Paper›PMID 25901069›Full record

ReviewCirculation2015

Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Gabriele G Schiattarella, Joseph A Hill

Open access · bronzeAbstract readReview
In one paragraph

Review in Circulation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 242 citations in OpenAlex.

  1. Article
  2. Glutamine Metabolism in Cardiac Hypertrophy.Reviews in cardiovascular medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cellular basis of HFpEF: contributions of abnormal lipids.Frontiers in cardiovascular medicine · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. CD163Basic research in cardiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gabriele G SchiattarellaFrom Departments of Internal Medicine (Cardiology) (G.G.S., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX.
Joseph A HillFrom Departments of Internal Medicine (Cardiology) (G.G.S., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX. joseph.hill@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · US

Funding

Microenvironmental control of progenitors in organ dysfunction and repairU01HL100401 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI OLSON, ERIC N, SCHNEIDER, JAY W · 2009 to 2015
$8.3M
STIM1: Master Regulator of Calcium Homeostasis in CardiomyocytesR01HL120732 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2013 to 2016
$1.6M
NHLBI NIH HHS HL-100401NHLBI NIH HHS HL-120732NHLBI NIH HHS R01 HL120732NHLBI NIH HHS U01 HL100401
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCell DeathEndothelium, VascularFibrosisGene Expression RegulationHeart Conduction SystemHistone Deacetylase InhibitorsHumansHypertensionHypertrophy, Left VentricularMacrophagesMyocytes, CardiacVentricular RemodelingHistone Deacetylase Inhibitors

Identifiers

PMID25901069
PMCPMC4408778
OpenAlexW1998860713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.